Research ArticleAccepted Article
Including pain, fatigue and physical function when assessing patients with early rheumatoid arthritis provides a comprehensive picture of disease burden
Sofia Pazmino, Anikó Lovik, Annelies Boonen, Diederik De Cock, Veerle Stouten, Johan Joly, Delphine Bertrand, Kristien van der Elst, René Westhovens and Patrick Verschueren
The Journal of Rheumatology November 2020, jrheum.200758; DOI: https://doi.org/10.3899/jrheum.200758
Sofia Pazmino
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
Anikó Lovik
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
Annelies Boonen
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
Diederik De Cock
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
Veerle Stouten
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
Johan Joly
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
Delphine Bertrand
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
Kristien van der Elst
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
René Westhovens
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
Patrick Verschueren
Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Funding: The CareRA trial (EudraCT number: 2008-007225-39) was funded by a Flemish governmental grant (Agency for Innovation by Science and Technology [IWT]). Patrick Verschueren holds the Pfizer chair for early rheumatoid arthritis management at the KU Leuven. Address correspondence to Sofia Pazmino, Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. E-mail: sofia.pazmino@kuleuven.be
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Including pain, fatigue and physical function when assessing patients with early rheumatoid arthritis provides a comprehensive picture of disease burden
Sofia Pazmino, Anikó Lovik, Annelies Boonen, Diederik De Cock, Veerle Stouten, Johan Joly, Delphine Bertrand, Kristien van der Elst, René Westhovens, Patrick Verschueren
The Journal of Rheumatology Nov 2020, jrheum.200758; DOI: 10.3899/jrheum.200758
Accepted manuscript
Including pain, fatigue and physical function when assessing patients with early rheumatoid arthritis provides a comprehensive picture of disease burden
Sofia Pazmino, Anikó Lovik, Annelies Boonen, Diederik De Cock, Veerle Stouten, Johan Joly, Delphine Bertrand, Kristien van der Elst, René Westhovens, Patrick Verschueren
The Journal of Rheumatology Nov 2020, jrheum.200758; DOI: 10.3899/jrheum.200758